Foghorn Therapeutics Inc. (FHTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Foghorn Therapeutics Inc. on February 23, 2026. The filing discloses a significant change in executive leadership, specifically the appointment of a new Chief Financial Officer (CFO) and the departure of the interim CFO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel changes and compensation arrangements.
Material Changes
- Appointment of CFO: Ryan D. Maynard was appointed as Chief Financial Officer, effective February 23, 2026. He will serve as the Company's principal financial officer and principal accounting officer.
- Departure of Interim CFO: Jeff Sacher ceased serving as Interim Chief Financial Officer, principal financial officer, and principal accounting officer in connection with Mr. Maynard's appointment.
- Compensation Package: Mr. Maynard's employment agreement includes:
- Annual base salary: $510,000
- Target annual performance bonus: 40% of base salary
- Signing bonus: $90,000
- Stock options: 400,000 shares under the 2020 Equity Incentive Plan, vesting 25% on the first anniversary and the remaining 75% in equal quarterly installments over the subsequent 12 quarters.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding the Company's business strategy or market conditions. No specific risks or contingencies related to the Company's operations are disclosed in this report, other than the standard disclosure that the summary of the employment agreement is qualified by reference to the full text of the agreement.
Key Facts for Investor Verification
- Verify the vesting schedule and exercise price of the 400,000 stock options granted to the new CFO.
- Confirm the effective date of the transition between the interim and permanent CFO roles.
- Review the full text of the Employment Agreement (Exhibit 10.1) for any additional terms, such as severance provisions or change-of-control clauses not detailed in the summary.
- Assess the impact of the new CFO's background (previously CFO at Cara Therapeutics, LetsGetChecked, Blade Therapeutics, and Rigel Pharmaceuticals) on the Company's financial strategy.